Johan Gobom

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/571258/publications.pdf

Version: 2024-02-01

63 papers	2,273 citations	257450 24 h-index	223800 46 g-index
68 all docs	68 docs citations	68 times ranked	3033 citing authors

#	Article	IF	Citations
1	Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected nonâ€Alzheimer's disease pathophysiology. Alzheimer's and Dementia, 2023, 19, 807-820.	0.8	4
2	Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. Clinical Chemistry and Laboratory Medicine, 2022, 60, 207-219.	2.3	44
3	Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimerâ€™s disease. Molecular Neurodegeneration, 2022, 17, 27.	10.8	30
4	Effects of age, amyloid, sex, and APOE Îµ4 on the CSF proteome in normal cognition. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12286.	2.4	4
5	Optimized sample preparation and data analysis for TMT proteomic analysis of cerebrospinal fluid applied to the identification of Alzheimerâ€™s disease biomarkers. Clinical Proteomics, 2022, 19, 13.	2.1	10
6	Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5â€“90 years. Brain Communications, 2022, 4, .	3.3	57
7	Increased CSF-decorin predicts brain pathological changes driven by Alzheimerâ€™s AÎ² amyloidosis. Acta Neuropathologica Communications, 2022, 10, .	5.2	8
8	Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12179.	2.4	35
9	Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers. Acta Neuropathologica Communications, 2021, 9, 19.	5.2	17
10	The influence of the R47H triggering receptor expressed on myeloid cells 2 variant on microglial exosome profiles. Brain Communications, 2021, 3, fcab009.	3.3	7
11	Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease. Journal of Internal Medicine, 2021, 290, 583-601.	6.0	54
12	Genome-scale metabolic network reconstruction of model animals as a platform for translational research. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	48
13	CSF Proteomic Alzheimerâ€™s Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. Proteomes, 2021, 9, 36.	3.5	9
14	A mass spectrometric approach to study the interaction of amyloid Î² peptides with human Î±-2-macroglobulin. Biochimie, 2021, 191, 62-68.	2.6	4
15	Differential Stimulation of Pluripotent Stem Cell-Derived Human Microglia Leads to Exosomal Proteomic Changes Affecting Neurons. Cells, 2021, 10, 2866.	4.1	6
16	Decorin is an early CSF biomarker of Alzheimerâ€™s AÎ² amyloidosis. Alzheimer's and Dementia, 2021, 17, .	0.8	0
17	Alzheimerâ€™s disease genetic risk variants show brain cell typeâ€specific associations with protein levels in cerebrospinal fluid. Alzheimer's and Dementia, 2021, 17, e049531.	0.8	0
18	Mass spectrometric measurement of six siteâ€specific tau phosphorylations in CSF and blood of Alzheimer's disease patients. Alzheimer's and Dementia, 2021, 17, .	0.8	0

#	Article	IF	Citations
19	A novel antibodyâ€free mass spectrometry panel of CSF biomarkers for synaptic dysfunction. Alzheimer's and Dementia, 2021, 17, .	0.8	1
20	Cerebrospinal fluid proteomic profiling of individuals with prodromal Alzheimerâ€™s disease classified using two different neurodegenerative biomarkers (N) in A/T/N classification. Alzheimer's and Dementia, 2021, 17, e053030.	0.8	0
21	Immune protein levels in cerebrospinal fluid: Associations with memory scores across the AD spectrum.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e055451.	0.8	0
22	Protein aggregate formation permits millennium-old brain preservation. Journal of the Royal Society Interface, 2020, 17, 20190775.	3.4	11
23	First amyloid Î²1â€42 certified reference material for reâ€calibrating commercial immunoassays. Alzheimer's and Dementia, 2020, 16, 1493-1503.	0.8	42
24	A novel proteomics assay allows parallel quantitation of a panel of synaptic proteins in human cerebrospinal fluid. Alzheimer's and Dementia, 2020, 16, e042578.	0.8	0
25	Synaptic proteins relate to memory scores in preclinical Alzheimerâ€™s disease and cognitively healthy controls depending on amyloid. Alzheimer's and Dementia, 2020, 16, e046102.	0.8	0
26	CSF proteomic profiling of mild cognitive impairment individuals with suspected nonâ€Alzheimerâ€™s disease pathophysiology. Alzheimer's and Dementia, 2020, 16, e047247.	0.8	1
27	Ultraâ€performance liquid chromatographyâ€tandem mass spectrometry method for analysis of tau in human cerebrospinal fluid without the need of immunocapture. Alzheimer's and Dementia, 2020, 16, e040373.	0.8	0
28	Author reply to the Letter to the Editor by Prof.Dr. Dr Mischak: â€œReâ€analysis of peptidomic analysis of cartilage and subchondral bone in OA patientsâ€. European Journal of Clinical Investigation, 2020, 50, e13260.	3.4	0
29	APOE Îµ4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 65.	6.2	28
30	Pathophysiological subtypes of Alzheimerâ€™s disease based on cerebrospinal fluid proteomics. Brain, 2020, 143, 3776-3792.	7.6	89
31	Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimerâ€™s disease. Clinical Mass Spectrometry, 2019, 14, 74-82.	1.9	9
32	Peptidomic analysis of cartilage and subchondral bone in OA patients. European Journal of Clinical Investigation, 2019, 49, e13082.	3.4	6
33	P4â€525: ASSOCIATION OF CSF TAU WITH HYPERPLASTICITY IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P1515.	0.8	0
34	Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimerâ€™s disease. Acta Neuropathologica, 2019, 137, 279-296.	7.7	128
35	Fluidâ€based proteomics targeted on pathophysiological processes and pathologies in neurodegenerative diseases. Journal of Neurochemistry, 2019, 151, 417-434.	3.9	15
36	O3â€14â€04: THE PROTEINâ€TOâ€PEPTIDE RATIO IMPROVES THE PERFORMANCE OF MICROTUBULEâ€ASSOCIATED PROTEIN TAU IN CSF AS AN ALZHEIMER BIOMARKER. Alzheimer's and Dementia, 2018, 14, P1060.	0.8	0

#	Article	IF	Citations
37	Levels of ADAM10 are reduced in Alzheimerâ€™s disease CSF. Journal of Neuroinflammation, 2018, 15, 213.	7.2	39
38	Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics. Parkinsonism and Related Disorders, 2017, 37, 65-71.	2.2	34
39	Expanding the cerebrospinal fluid endopeptidome. Proteomics, 2017, 17, 1600384.	2.2	28
40	Proteomic studies of cerebrospinal fluid biomarkers of Alzheimerâ€™s disease: an update. Expert Review of Proteomics, 2017, 14, 1007-1020.	3.0	21
41	A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimerâ€™s disease. Scientific Reports, 2017, 7, 13333.	3.3	45
42	Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid Î² clearance pathway. Molecular Neurodegeneration, 2017, 12, 18.	10.8	17
43	[P3â€“084]: Nâ€TERMINAL FRAGMENT OF TAU: ASSAY DEVELOPMENT WITH INâ€HOUSE CLEAVAGEâ€SPECIFIC ANTIBODY. Alzheimer's and Dementia, 2017, 13, P964.	0.8	0
44	[P2â€“246]: NOVEL CSF FRAGMENTS OF TAU: CANDIDATE BIOMARKERS OF ALZHEIMER's DISEASE AND TAUOPATHIES. Alzheimer's and Dementia, 2017, 13, P706.	0.8	0
45	Sample Preparation for Endopeptidomic Analysis in Human Cerebrospinal Fluid. Journal of Visualized Experiments, 2017, , .	0.3	1
46	[P4â€“382]: PROTEOMIC CHANGES IN ZEBRAFISH LACKING THE AMYLOID PRECURSOR HOMOLOG, APPB, USING A HIGHâ€THROUGHPUT DIFFERENTIAL PROTEOMIC APPROACH. Alzheimer's and Dementia, 2017, 13, P1439.	0.8	0
47	[P3â€“075]: PLEIOTROPHIN, A NEW BIOMARKER FOR AD, IDENTIFIED USING A NOVEL STRATEGY IN CLINICAL PROTEOMICS. Alzheimer's and Dementia, 2017, 13, P960.	0.8	0
48	Comprehensive Quantitative Profiling of Tau and Phosphorylated Tau Peptides in Cerebrospinal Fluid by Mass Spectrometry Provides New Biomarker Candidates. Journal of Alzheimer's Disease, 2016, 55, 303-313.	2.6	44
49	Reference measurement procedure for <scp>CSF</scp> amyloid beta (Aβ2)_{1–42} and the <scp>CSF</scp> Aβ2_{1–42}/Aβ2_{1–40} ratio – a cross‐validation study against amyloid <scp>PET</scp>. Journal of Neurochemistry, 2016, 139, 651-658.	3.9	78
50	A single dose of the Î³-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans. Alzheimer's Research and Therapy, 2016, 8, 11.	6.2	15
51	Round robin test on quantification of amyloidâ€Îβ2 1â€“42 in cerebrospinal fluid by mass spectrometry. Alzheimer's and Dementia, 2016, 12, 55-59.	0.8	46
52	An Integrated Workflow for Multiplex CSF Proteomics and Peptidomicsâ€”Identification of Candidate Cerebrospinal Fluid Biomarkers of Alzheimerâ€™s Disease. Journal of Proteome Research, 2015, 14, 654-663.	3.7	84
53	Explorative and targeted neuroproteomics in Alzheimer's disease. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2015, 1854, 769-778.	2.3	41
54	Advancing cerebrospinal fluid biomarker discovery by mass spectrometry. Neurodegenerative Disease Management, 2015, 5, 371-373.	2.2	4

#	Article	IF	Citations
55	The amyloid-Î² degradation pattern in plasmaâ€"A possible tool for clinical trials in Alzheimer's disease. Neuroscience Letters, 2014, 573, 7-12.	2.1	62
56	Mass Spectrometryâ€"Based Candidate Reference Measurement Procedure for Quantification of Amyloid-Î² in Cerebrospinal Fluid. Clinical Chemistry, 2014, 60, 987-994.	3.2	132
57	Peptidome Analysis of Cerebrospinal Fluid by LC-MALDI MS. PLoS ONE, 2012, 7, e42555.	2.5	57
58	Targeted proteomics in Alzheimerâ€™s disease: focus on amyloid-Î². Expert Review of Proteomics, 2008, 5, 225-237.	3.0	49
59	Method for Qualitative Comparisons of Protein Mixtures Based on Enzyme-Catalyzed Stable-Isotope Incorporation. Journal of Proteome Research, 2005, 4, 2109-2116.	3.7	14
60	Arginine vasopressin in the cytoplasm and nuclear fraction of lymphocytes from healthy donors and patients with depression or schizophrenia. Peptides, 2001, 22, 67-72.	2.4	23
61	Detection and Quantification of Neurotensin in Human Brain Tissue by Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry. Analytical Chemistry, 2000, 72, 3320-3326.	6.5	84
62	Sample purification and preparation technique based on nano-scale reversed-phase columns for the sensitive analysis of complex peptide mixtures by matrix-assisted laser desorption/ionization mass spectrometry. Journal of Mass Spectrometry, 1999, 34, 105-116.	1.6	679
63	Sample purification and preparation technique based on nano-scale reversed-phase columns for the sensitive analysis of complex peptide mixtures by matrix-assisted laser desorption/ionization mass spectrometry. Journal of Mass Spectrometry, 1999, 34, 105.	1.6	4